VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease
Reason given: Sponsor Decision
Key facts
- Where
- Atlanta, Chevy Chase, Columbus, Garden Grove, Garland, Glenview, Gurnee, Katy, Kissimmee, Lancaster, Liberty, Louisville, Lubbock, Miami, Myrtle Beach, New Albany, Oklahoma City, Orlando, Rockville, Shreveport, Southlake, Tyler, West Jordan, and Winston-Salem, United StatesSee the 26 sites
- Phase
- Phase 2
Where in United States
- AtlantaAtlanta, United StatesNo longer taking part
- Chevy ChaseChevy Chase, United StatesNo longer taking part
- ColumbusColumbus, United StatesNo longer taking part
- Garden GroveGarden Grove, United StatesNo longer taking part
- GarlandGarland, United StatesNo longer taking part
- GlenviewGlenview, United StatesNo longer taking part
- GurneeGurnee, United StatesNo longer taking part
- KatyKaty, United StatesNo longer taking part
- KissimmeeKissimmee, United StatesNo longer taking part
- LancasterLancaster, United StatesNo longer taking part
- LibertyLiberty, United StatesNo longer taking part
- LouisvilleLouisville, United StatesNo longer taking part
- LubbockLubbock, United StatesNo longer taking part
- LubbockLubbock, United StatesNo longer taking part
- MiamiMiami, United StatesNo longer taking part
- Myrtle BeachMyrtle Beach, United StatesNo longer taking part
- New AlbanyNew Albany, United StatesNo longer taking part
- Oklahoma CityOklahoma City, United StatesNo longer taking part
- OrlandoOrlando, United StatesNo longer taking part
- OrlandoOrlando, United StatesNo longer taking part
- RockvilleRockville, United StatesNo longer taking part
- ShreveportShreveport, United StatesNo longer taking part
- SouthlakeSouthlake, United StatesNo longer taking part
- TylerTyler, United StatesNo longer taking part
- West JordanWest Jordan, United StatesNo longer taking part
- Winston-SalemWinston-Salem, United StatesNo longer taking part
Trial details
- Who runs it
- Ventyx Biosciences, Inc
- Trial code
- NCT05688852
- Record updated
- 3 July 2025
- Original description
This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease
This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.
Inclusion: Men or women, 18 to 75 years of age, inclusive, at the time of consent; Capable of giving signed informed consent; Documented diagnosis of CD ≥ 3 months prior to Day 1. The diagnosis of CD must be confirmed by clinical, endoscopic, and histologic evidence; Moderately to severely active CD.
Exclusion: Presence of currently known complications of CD such as symptomatic bowel stricture(s) and >2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, left and sigmoid colon, and rectum, fulminant colitis, toxic megacolon or any other manifestation that may require surgery or hospitalization; Previous exposure to VTX958 or any other TYK2 inhibitor (eg, deucravacitinib) in any study; Known diagnosis of short gut or bowel syndrome; Current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, or infectious colitis; Presence of a stoma or ileoanal pouch.